Naiyer A. Rizvi
Columbia University in the City of New York
H-index: 89
North America-United States
Top articles of Naiyer A. Rizvi
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132) | Cancer Research | Benjamin Izar Dmitriy Zamarin David R Spigel Christopher J Hoimes David F McDermott | 2024/4/5 |
Metabolic augmentation to promote and enhance immune response by tcf1+ t cell repopulation | 2024/1/25 | ||
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors | Cell Reports Medicine | Shoiab Bukhari Brian S Henick Robert J Winchester Shalom Lerrer Kieran Adam | 2023/1/17 |
Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in … | Cancer Research | Maria Lia Palomba Matthew G Mei Paolo F Caimi Matthew Cortese Marco Davila | 2023/4/14 |
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC | Journal of Thoracic Oncology | Gilberto de Castro Jr Naiyer A Rizvi Peter Schmid Konstantinos Syrigos Claudio Martin | 2023/1/1 |
Abstract CT217: 3-year update of neoadjuvant atezolizumab+ chemotherapy in patients with resectable non-small cell lung cancer | Cancer Research | Brian S Henick Justin F Gainor Mark M Awad Codruta Chiuzan Stephanie Izard | 2023/4/14 |
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development | Journal for immunotherapy of cancer | Hussein A Tawbi Ryan J Sullivan David Feltquate Theresa LaVallee Naiyer A Rizvi | 2023 |
Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer | Cancer Research | Vivek Naranbhai Arvind Ravi Matthew Hellmann Monica Arniella Mark Holton | 2023/4/4 |
International Association for the Study of Lung Cancer study of reproducibility in assessment of pathologic response in resected lung cancers after neoadjuvant therapy | JOURNAL OF THORACIC ONCOLOGY | Mp Smeltzer Gv Scagliotti Ha Wakalee T Mitsudomi Ub Roy | 2022 |
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy | Journal for immunotherapy of cancer | Jarushka Naidoo Catherine Murphy Michael B Atkins Julie R Brahmer Stephane Champiat | 2023 |
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab | Cancer Research | Tyler Joseph Alban Nadeem Riaz Prerana Parthasarathy Vlad Makarov Slav Kendall | 2023/4/4 |
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer | Nature genetics | Arvind Ravi Matthew D Hellmann Monica B Arniella Mark Holton Samuel S Freeman | 2023/5 |
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy | Cancer immunology research | Rohan Maniar Peter H Wang Robert S Washburn Radomir Kratchmarov Shana M Coley | 2023/2/3 |
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications | Journal for Immunotherapy of Cancer | Mario Sznol Naiyer Rizvi | 2023 |
Baseline radiomic signature to estimate overall survival in patients with NSCLC | Journal of Thoracic Oncology | Laurent Dercle Matthew Fronheiser Naiyer A Rizvi Matthew D Hellmann Sabine Maier | 2023/5/1 |
Assessing pathologic response in resected lung cancers: current standards, proposal for a novel pathologic response calculator tool, and challenges in practice | Anjali Saqi Kevin O Leslie Andre L Moreira Sylvie Lantuejoul Catherine Ann Shu | 2022/5/1 | |
Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer | Cancer Research | Arvind Ravi Justin Gainor Monica Arniella Chip Stewart Sam Freeman | 2022/6/15 |
Integrative analysis of checkpoint blockade response in advanced non-small cell lung cancer | bioRxiv | Arvind Ravi Justin F Gainor Monica B Arniella Mark Holton Samuel S Freeman | 2022/3/23 |
Abstract CT244: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors … | Cancer Research | David Spigel Alexander Spira Dmitriy Zamarin David F McDermott Jason Luke | 2022/6/15 |
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors | Journal for immunotherapy of cancer | Omid Hamid Alberto A Chiappori John A Thompson Toshihiko Doi Siwen Hu-Lieskovan | 2022 |
